Slowly folding surface extension in the prototypic avian hepatitis B virus capsid governs stability
- Elife. 2020 Aug 14;9:e57277. doi: 10.7554/eLife.57277.
- 1. Julius Maximilian University of Würzburg, Department of Biochemistry and Rudolf Virchow Centre, Würzburg, Germany.
- 2. University Hospital Freiburg, Internal Medicine 2/Molecular Biology, Freiburg, Germany.
- # Contributed equally.
Hepatitis B virus (HBV) is an important but difficult to study human pathogen. Most basics of the hepadnaviral life-cycle were unraveled using duck HBV (DHBV) as a model although DHBV has a capsid protein (CP) comprising ~260 rather than ~180 Amino acids. Here we present high-resolution structures of several DHBV capsid-like particles (CLPs) determined by electron cryo-microscopy. As for HBV, DHBV CLPs consist of a dimeric α-helical frame-work with protruding spikes at the dimer interface. A fundamental new feature is a ~ 45 amino acid proline-rich extension in each monomer replacing the tip of the spikes in HBV CP. In vitro, folding of the extension takes months, implying a catalyzed process in vivo. DHBc variants lacking a folding-proficient extension produced regular CLPs in bacteria but failed to form stable nucleocapsids in hepatoma cells. We propose that the extension domain acts as a conformational switch with differential response options during viral Infection.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: Biochemical Assay ReagentsResearch Areas: Others
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
98.0%, Non-Cleavable ADC LinkerResearch Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
98.01%, E3 Ligase Ligand-Linker ConjugatesResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer